Cassava Sciences Stock News

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $49.22, moving +1.07% from the previous trading session.

Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks

The FDA Deals Another Blow To Cassava Sciences' Bears

Benzinga's “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news items possibly impacting those stocks.

After dropping since mid-November, the price of Cassava Sciences stock (SAVA) has bounced back and today it is up 7.78%. The current bullish outlook is a result of a denial by the FDA against Citizen

AUSTIN, Texas, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that the U.S. Food an

Most treatments for Alzheimer's disease either lead to only temporary improvements or only minimally slow down the progression of the disease. Read what makes investors positive on Anavex...

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $47.12, moving +0.17% from the previous trading session.

Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows.

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling. Sh

As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. The post Keep an Eye on $60 as a Target Price for Cassava Sc

Cassava Sciences Inc (SAVA) shares closed this week 20.3% higher than it did at the end of last week. The stock is currently up 9.4% year-to-date, down 24.6% over the past 12 months, and up 1124.9% over the past five years. This week, the Dow Jones Industrial Average rose 1.1%, and the S&P 500 rose 1.5%. Trading Activity Shares traded as high as $49.75 and as low as $39.84 this week.Shares closed 67.3% below its 52-week high and 52.1% above its 52-week low.Trading volume this week was 44.5% lower than the 10-day average and 51.9% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 2.4. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 4.4% higher than its 5-day moving average, 10.2% higher than its 20-day moving average, and 5.3% lower than its 90-day moving average. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and beats it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and beats it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -1217.9% The company's stock price performance over the past 12 months lags the peer average by 57.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cassava Sciences, Inc. (SAVA) closed the most recent trading day at $45.73, moving -0.61% from the previous trading session.

Seeking Alpha longs have warned that increasing short positions in Cassava Sciences stock could result in a “short squeeze.”. For at least several days, comments on Seeking Alpha have disclosed th